Highlights
- Market Cap
- $4.11B
- Enterprise Value
- $6.06B
- EPS (TTM)
- $0.27
- PE Ratio
- 52.67
- PEG Ratio
- 102.52
- Total Revenue (TTM)
- $1.16B
- Gross Profit (TTM)
- $645.53M
- EBITDA (TTM)
- $392.77M
- Year Range
- $9.53 - $19.85
- Target Price
- $22.67
- ROA (TTM)
- 2.39%
- ROE (TTM)
- 12.86%
Share Price Chart
Loading graphics...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Sotera Health Company, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Loading graphics...
Returns By Period
Sotera Health Company (SHC) has returned -18.71% so far this year and 22.98% over the past 12 months.
Sotera Health Company
- 1D
- 8.23%
- 1M
- -11.75%
- YTD
- -18.71%
- 6M
- -8.84%
- 1Y
- 22.98%
- 3Y*
- -7.14%
- 5Y*
- -10.54%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 2.91%
- 1M
- -5.09%
- YTD
- -4.63%
- 6M
- -2.39%
- 1Y
- 16.33%
- 3Y*
- 16.69%
- 5Y*
- 10.18%
- 10Y*
- 12.16%
Monthly Returns
Based on dividend-adjusted daily data since Nov 20, 2020, SHC's average daily return is +0.03%, while the average monthly return is +0.70%. At this rate, your investment would double in approximately 8.3 years.
Historically, 49% of months were positive and 51% were negative. The best month was Jan 2023 with a return of +107.0%, while the worst month was Sep 2022 at -59.7%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 4 months.
On a daily basis, SHC closed higher 47% of trading days. The best single day was Jan 10, 2023 with a return of +99.7%, while the worst single day was Sep 19, 2022 at -33.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.72% | -10.32% | -11.75% | -18.71% | |||||||||
| 2025 | 0.22% | -9.04% | -6.50% | -1.37% | 6.43% | -9.15% | 3.33% | 42.47% | -3.91% | 5.53% | 5.30% | 0.92% | 28.95% |
| 2024 | -12.64% | 1.97% | -19.99% | -6.74% | -0.18% | 6.17% | 16.85% | 11.32% | 8.16% | -6.17% | -15.95% | 3.87% | -18.81% |
| 2023 | 106.96% | -3.19% | 7.31% | -6.37% | -15.98% | 33.71% | 0.74% | -14.96% | -7.19% | -15.49% | 7.82% | 23.44% | 102.28% |
| 2022 | -8.66% | 1.67% | -0.96% | -5.91% | 4.51% | -8.03% | -1.99% | -11.93% | -59.67% | 0.88% | 21.22% | -0.12% | -64.63% |
| 2021 | -4.92% | 0.23% | -4.55% | 3.21% | -6.44% | 0.54% | -2.19% | 3.21% | 6.91% | -5.54% | -13.60% | 10.36% | -14.18% |
Benchmark Metrics
Sotera Health Company has an annualized alpha of -8.44%, beta of 1.18, and R² of 0.10 versus S&P 500 Index. Calculated based on daily prices since November 23, 2020.
- This stock participated in 191.76% of S&P 500 Index downside but only 123.98% of its upside — more exposed to losses than it benefited from rallies.
- R² of 0.10 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -8.44%
- Beta
- 1.18
- R²
- 0.10
- Upside Capture
- 123.98%
- Downside Capture
- 191.76%
Return for Risk
Risk / Return Rank
SHC ranks 59 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Sotera Health Company (SHC) and compare them to a chosen benchmark (S&P 500 Index).
| SHC | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 0.53 | 0.90 | -0.37 |
Sortino ratioReturn per unit of downside risk | 1.31 | 1.39 | -0.08 |
Omega ratioGain probability vs. loss probability | 1.15 | 1.21 | -0.06 |
Calmar ratioReturn relative to maximum drawdown | 0.68 | 1.40 | -0.72 |
Martin ratioReturn relative to average drawdown | 1.92 | 6.61 | -4.68 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Explore SHC risk-adjusted metrics in detail
Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading graphics...
Worst Drawdowns
The table below displays the maximum drawdowns of the Sotera Health Company. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Sotera Health Company was 79.47%, occurring on Nov 17, 2022. The portfolio has not yet recovered.
The current Sotera Health Company drawdown is 50.52%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -79.47% | Mar 15, 2021 | 426 | Nov 17, 2022 | — | — | — |
| -10.68% | Dec 3, 2020 | 25 | Jan 8, 2021 | 27 | Feb 18, 2021 | 52 |
| -9.12% | Feb 19, 2021 | 12 | Mar 8, 2021 | 3 | Mar 11, 2021 | 15 |
| -4.26% | Nov 24, 2020 | 2 | Nov 25, 2020 | 1 | Nov 27, 2020 | 3 |
| -3.25% | Nov 30, 2020 | 1 | Nov 30, 2020 | 2 | Dec 2, 2020 | 3 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading graphics...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Sotera Health Company over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Sotera Health Company is priced in the market compared to other companies in the Diagnostics & Research industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for SHC, comparing it with other companies in the Diagnostics & Research industry. Currently, SHC has a P/E ratio of 52.7. This P/E ratio is significantly higher than those of industry peers. This could indicate that the stock is overvalued or that investors expect strong future growth.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for SHC compared to other companies in the Diagnostics & Research industry. SHC currently has a PEG ratio of 102.5. This PEG ratio is higher than the industry average, which may suggest the stock is overvalued relative to its expected earnings growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for SHC relative to other companies in the Diagnostics & Research industry. Currently, SHC has a P/S ratio of 3.5. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for SHC in comparison with other companies in the Diagnostics & Research industry. Currently, SHC has a P/B value of 6.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |